Your browser doesn't support javascript.
loading
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood, John M; Gonzalez, Rene; Reintgen, Douglas; Clingan, Philip R; McWilliams, Robert R; de Alwis, Dinesh P; Zimmermann, Annamaria; Brown, Michael P; Ilaria, Robert L; Millward, Michael J.
Affiliation
  • Kirkwood JM; Melanoma and Skin Cancer Program, University of Pittsburgh Medical Center, Pennsylvania, USA. kirkwoodjm@pmc.edu
Cancer ; 117(20): 4732-9, 2011 Oct 15.
Article in En | MEDLINE | ID: mdl-21456002
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Sulfonamides / Benzamides / Antineoplastic Combined Chemotherapy Protocols / Apoptosis / Angiogenesis Inhibitors / Melanoma Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2011 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Sulfonamides / Benzamides / Antineoplastic Combined Chemotherapy Protocols / Apoptosis / Angiogenesis Inhibitors / Melanoma Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2011 Document type: Article Affiliation country: United States Country of publication: United States